Kuehn Law Investigates Corcept Executives' Fiduciary Duties
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Source: PRnewswire
- Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether Corcept Therapeutics executives breached their fiduciary duties to shareholders, as a federal lawsuit alleges the company failed to disclose adverse information regarding FDA approval, potentially harming shareholder interests.
- FDA Approval Risks: While promoting the prospects of FDA approval for relacorilant, Corcept did not disclose the FDA's concerns about the adequacy of its clinical development program, indicating that the New Drug Application faces a significant risk of rejection, which could lead to shareholder losses.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased CORT stock before October 31, 2024, to contact the firm promptly to enforce their rights within a limited timeframe, emphasizing the importance of shareholder participation in maintaining market integrity.
- No Legal Fees: Kuehn Law assures that all case costs will be covered for investor clients, ensuring that shareholders do not incur additional financial burdens while pursuing their legal rights, thereby enhancing confidence in the legal process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 81.560
Low
50.00
Averages
91.00
High
121.00
Current: 81.560
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kuehn Law Investigates Corcept Executives' Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether Corcept Therapeutics' executives and directors breached their fiduciary duties to shareholders, as a federal securities lawsuit claims the company failed to disclose adverse information regarding FDA approval, potentially harming shareholder interests.
- FDA Approval Risks: While Corcept promoted the expected success of its new drug relacorilant, it did not disclose that the FDA had raised concerns about the adequacy of its clinical development program, and that the New Drug Application faced a significant risk of rejection, which could impact the company's market performance and shareholder confidence.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased CORT stock before October 31, 2024, to contact the firm promptly to protect their rights, highlighting the urgency and necessity of legal action that may influence investor decisions.
- Importance of Market Integrity: By participating in such legal actions, shareholders not only protect their own interests but also contribute to the integrity and fairness of financial markets, emphasizing the crucial role of investors in corporate governance.
See More
Kuehn Law Investigates Corcept Executives' Fiduciary Duties
- Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether Corcept Therapeutics executives breached their fiduciary duties to shareholders, as a federal lawsuit alleges the company failed to disclose adverse information regarding FDA approval, potentially harming shareholder interests.
- FDA Approval Risks: While promoting the prospects of FDA approval for relacorilant, Corcept did not disclose the FDA's concerns about the adequacy of its clinical development program, indicating that the New Drug Application faces a significant risk of rejection, which could lead to shareholder losses.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased CORT stock before October 31, 2024, to contact the firm promptly to enforce their rights within a limited timeframe, emphasizing the importance of shareholder participation in maintaining market integrity.
- No Legal Fees: Kuehn Law assures that all case costs will be covered for investor clients, ensuring that shareholders do not incur additional financial burdens while pursuing their legal rights, thereby enhancing confidence in the legal process.
See More
Three Unpopular Stocks We Avoid
- Amtech's Struggles: Amtech Systems (NASDAQ:ASYS) has experienced a 14.9% annual sales decline over the past two years, indicating its products have failed to connect with the market, resulting in an operating margin of -0.7%, which is significantly below the industry average, thus impacting its profitability and competitive position.
- American Airlines' Financial Pressure: American Airlines (NASDAQ:AAL) faces a high net debt-to-EBITDA ratio of 7x, which could force the company to raise capital under unfavorable terms if market conditions deteriorate, while its revenue passenger miles performance has lagged behind peers, indicating that management's investments are failing to create value.
- Corcept's Declining Profitability: Corcept Therapeutics (NASDAQ:CORT) has seen its earnings per share fall by 19.4% annually over the last five years, despite revenue growth, with free cash flow margin shrinking by 31 percentage points, suggesting the company is consuming more capital to remain competitive, thus facing challenges in profitability.
- Uncertain Market Outlook: These three stocks share the commonality of declining profitability and weakened market competitiveness, prompting investors to exercise caution regarding their investment value while considering other stocks with greater growth potential.
See More
Kuehn Law Investigates Corcept Executives for Fiduciary Breach
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether Corcept Therapeutics executives breached their fiduciary duties to shareholders, as a federal lawsuit alleges the company failed to disclose adverse information regarding FDA approval, potentially harming shareholder interests.
- FDA Approval Risks: While the company touted the expected success of its new drug relacorilant, the FDA expressed concerns about the adequacy of its clinical development program, resulting in a material risk of rejection for the New Drug Application, which could negatively impact the company's market outlook.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased CORT stock before October 31, 2024, to contact the firm promptly to enforce their rights, indicating the company's commitment to legal support and protective measures for investors.
- Call for Market Integrity: Kuehn Law emphasizes the importance of shareholder participation in maintaining the integrity and fairness of financial markets, encouraging investors to engage actively to safeguard their investments and future rights.
See More
Corcept Therapeutics Resubmits NDA for Relacorilant
- NDA Resubmission: Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, a candidate for Cushing's syndrome, including new data analyses aimed at addressing the FDA's request for additional data to advance the drug's approval process.
- FDA Feedback: The US FDA issued a Complete Response Letter in December, indicating that it could not determine a favorable benefit-risk assessment for the drug without further data, prompting the company to expedite data collection and analysis to meet regulatory requirements.
- Market Potential: Cushing's syndrome is characterized by high blood pressure related to a hormonal disorder, and relacorilant, as a selective glucocorticoid receptor antagonist, holds significant market potential, with projected sales for Cushing's expected to reach $2 billion by 2026.
- Financial Outlook: Corcept Therapeutics raised its revenue guidance for 2026 to between $950 million and $1.05 billion, reflecting strong market confidence in relacorilant and other products, further solidifying its position in the biopharmaceutical sector.
See More
Corcept Resubmits NDA for Relacorilant to Treat Cushing's Syndrome
- NDA Resubmission: Corcept Therapeutics has resubmitted its New Drug Application for relacorilant to the FDA for treating Cushing's syndrome, including additional analyses as requested, and expects a six-month review period, reflecting the company's confidence in advancing this treatment.
- Clinical Trial Evidence: The resubmission is supported by positive data from the pivotal GRACE trial and the double-blind, placebo-controlled Phase III GRADIENT trial, indicating that relacorilant effectively improves symptoms of Cushing's syndrome without causing serious adverse effects associated with current medications, enhancing its competitive edge in the market.
- Therapeutic Potential: As a selective glucocorticoid receptor antagonist, relacorilant modulates cortisol activity and may provide significant clinical benefits for many patients, particularly in alleviating hypertension, obesity, and diabetes symptoms, showcasing its broad application prospects in the treatment landscape.
- Company Overview: With over 25 years of experience in cortisol modulation, Corcept has developed more than 1,000 proprietary selective cortisol modulators and is leading advanced clinical trials for Cushing's syndrome and other serious disorders, further solidifying its position in the biopharmaceutical industry.
See More
Kuehn Law Investigates Corcept Executives' Fiduciary Duties
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether Corcept Therapeutics' executives and directors breached their fiduciary duties to shareholders, as a federal securities lawsuit claims the company failed to disclose adverse information regarding FDA approval, potentially harming shareholder interests.
- FDA Approval Risks: While Corcept promoted the expected success of its new drug relacorilant, it did not disclose that the FDA had raised concerns about the adequacy of its clinical development program, and that the New Drug Application faced a significant risk of rejection, which could impact the company's market performance and shareholder confidence.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased CORT stock before October 31, 2024, to contact the firm promptly to protect their rights, highlighting the urgency and necessity of legal action that may influence investor decisions.
- Importance of Market Integrity: By participating in such legal actions, shareholders not only protect their own interests but also contribute to the integrity and fairness of financial markets, emphasizing the crucial role of investors in corporate governance.
See More
Kuehn Law Investigates Corcept Executives' Fiduciary Duties
- Legal Investigation Initiated: Kuehn Law, PLLC is investigating whether Corcept Therapeutics executives breached their fiduciary duties to shareholders, as a federal lawsuit alleges the company failed to disclose adverse information regarding FDA approval, potentially harming shareholder interests.
- FDA Approval Risks: While promoting the prospects of FDA approval for relacorilant, Corcept did not disclose the FDA's concerns about the adequacy of its clinical development program, indicating that the New Drug Application faces a significant risk of rejection, which could lead to shareholder losses.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased CORT stock before October 31, 2024, to contact the firm promptly to enforce their rights within a limited timeframe, emphasizing the importance of shareholder participation in maintaining market integrity.
- No Legal Fees: Kuehn Law assures that all case costs will be covered for investor clients, ensuring that shareholders do not incur additional financial burdens while pursuing their legal rights, thereby enhancing confidence in the legal process.
See More
Three Unpopular Stocks We Avoid
- Amtech's Struggles: Amtech Systems (NASDAQ:ASYS) has experienced a 14.9% annual sales decline over the past two years, indicating its products have failed to connect with the market, resulting in an operating margin of -0.7%, which is significantly below the industry average, thus impacting its profitability and competitive position.
- American Airlines' Financial Pressure: American Airlines (NASDAQ:AAL) faces a high net debt-to-EBITDA ratio of 7x, which could force the company to raise capital under unfavorable terms if market conditions deteriorate, while its revenue passenger miles performance has lagged behind peers, indicating that management's investments are failing to create value.
- Corcept's Declining Profitability: Corcept Therapeutics (NASDAQ:CORT) has seen its earnings per share fall by 19.4% annually over the last five years, despite revenue growth, with free cash flow margin shrinking by 31 percentage points, suggesting the company is consuming more capital to remain competitive, thus facing challenges in profitability.
- Uncertain Market Outlook: These three stocks share the commonality of declining profitability and weakened market competitiveness, prompting investors to exercise caution regarding their investment value while considering other stocks with greater growth potential.
See More
Kuehn Law Investigates Corcept Executives for Fiduciary Breach
- Legal Investigation Launched: Kuehn Law, PLLC is investigating whether Corcept Therapeutics executives breached their fiduciary duties to shareholders, as a federal lawsuit alleges the company failed to disclose adverse information regarding FDA approval, potentially harming shareholder interests.
- FDA Approval Risks: While the company touted the expected success of its new drug relacorilant, the FDA expressed concerns about the adequacy of its clinical development program, resulting in a material risk of rejection for the New Drug Application, which could negatively impact the company's market outlook.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased CORT stock before October 31, 2024, to contact the firm promptly to enforce their rights, indicating the company's commitment to legal support and protective measures for investors.
- Call for Market Integrity: Kuehn Law emphasizes the importance of shareholder participation in maintaining the integrity and fairness of financial markets, encouraging investors to engage actively to safeguard their investments and future rights.
See More
Corcept Therapeutics Resubmits NDA for Relacorilant
- NDA Resubmission: Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, a candidate for Cushing's syndrome, including new data analyses aimed at addressing the FDA's request for additional data to advance the drug's approval process.
- FDA Feedback: The US FDA issued a Complete Response Letter in December, indicating that it could not determine a favorable benefit-risk assessment for the drug without further data, prompting the company to expedite data collection and analysis to meet regulatory requirements.
- Market Potential: Cushing's syndrome is characterized by high blood pressure related to a hormonal disorder, and relacorilant, as a selective glucocorticoid receptor antagonist, holds significant market potential, with projected sales for Cushing's expected to reach $2 billion by 2026.
- Financial Outlook: Corcept Therapeutics raised its revenue guidance for 2026 to between $950 million and $1.05 billion, reflecting strong market confidence in relacorilant and other products, further solidifying its position in the biopharmaceutical sector.
See More
Corcept Resubmits NDA for Relacorilant to Treat Cushing's Syndrome
- NDA Resubmission: Corcept Therapeutics has resubmitted its New Drug Application for relacorilant to the FDA for treating Cushing's syndrome, including additional analyses as requested, and expects a six-month review period, reflecting the company's confidence in advancing this treatment.
- Clinical Trial Evidence: The resubmission is supported by positive data from the pivotal GRACE trial and the double-blind, placebo-controlled Phase III GRADIENT trial, indicating that relacorilant effectively improves symptoms of Cushing's syndrome without causing serious adverse effects associated with current medications, enhancing its competitive edge in the market.
- Therapeutic Potential: As a selective glucocorticoid receptor antagonist, relacorilant modulates cortisol activity and may provide significant clinical benefits for many patients, particularly in alleviating hypertension, obesity, and diabetes symptoms, showcasing its broad application prospects in the treatment landscape.
- Company Overview: With over 25 years of experience in cortisol modulation, Corcept has developed more than 1,000 proprietary selective cortisol modulators and is leading advanced clinical trials for Cushing's syndrome and other serious disorders, further solidifying its position in the biopharmaceutical industry.
See More
